Abstract:Accurate estimation of biodistribution and absorbed dose to normal organs and tumors is important for immunoscintigraphic studies and radioimmunotherapy treatment planning. Methods: Four patients (3 men, 1 woman; mean age 54.8 +/- 9.2 yr; range 42-64 yr) were administered 3 mg of anti-human epidermal growth factor receptor (anti-hEGF-r) antibody (ior egf/r3), radiolabeled with 99mTc activity of 39.5 +/- 1.1 mCi (range 38.5 mCi-40.7 mCi) by intravenous bolus infusion. After administration, blood and urine samples were collected from three patients up to 24 hr after injection. Whole-body anterior and posterior scans were obtained at 5 min and 1, 3, 5 and 24 hr after injection. Using a computer program, regions of interest were drawn over the heart, liver, spleen, bladder and tumor to measure the activity in the source organs at each scanning time. Time-activity curves for each source organ were then fitted to monoexponential or biexponential functions by nonlinear least squares regression using the flexible polyhedrals method, which adequately fit our data with the correlation coefficient of 0.985 +/- 0.013, and were integrated to determine organ residence times. The mean absorbed doses to the whole body and various normal organs were then estimated from residence times and from blood and urine samples using the methods developed by the Medical Internal Radiation Dose Committee. The effective dose equivalent and effective dose were calculated as prescribed in ICRP Publication Nos. 30 and 60. Results: Plasma disappearance curves of 99mTc-labeled anti-hEGF-r antibody were best-fit by a two-compartment model in all patients with a distribution half-life (t(1/2alpha)) of 0.207 hr +/- 0.059 hr (mean +/- s.d., n = 3) and an elimination half-life (t(1/2beta)) of 13.9 hr +/- 2.2 hr. Among the various organs, significant accumulation of the radiolabeled antibody was found in the liver (48.5% +/- 4.4%, mean +/- s.d.), heart (3.50% +/- 0.17%) and spleen (3.1% +/- 1.8%) at 5 min postadministration. These values were reduced to 3.2% +/- 0.4%, 0.1% +/- 0.01% and 0.1% +/- 0.1%, respectively, at 24 hr. Mean cumulative urinary excretion of 99mTc-labeled anti-hEGF-r antibody was 4.6% +/- 0.6% at 24 hr postinjection. Estimates of radiation absorbed dose to normal organs in rad/mCi administered (mean +/- s.d., n = 4) were: whole body 0.017 +/- 0.002; gallbladder wall 0.074 +/- 0.007; spleen 0.136 +/- 0.076; and liver 0.267 +/- 0.036. The effective dose equivalent and effective dose estimates for adults were 0.041 +/- 0.008 rem/mCi and 0.027 +/- 0.004 rem/mCi administered. Conclusion: This feasibility study indicates that 99mTc-labeled anti-hEGF-r antibody (ior egf/r3) can be used safely; this analysis provides a dosimetric framework for future studies. This monoclonal antibody, labeled with 188Re, could possibly permit a successful regional radioimmunotherapy of tumors of epithelial origin.

Pharmacokinetics of technetium-99m labeled anti-hepatoma monoclonal antibody HAb18 and it's F(ab')2 fragment in mice

Mouse Extrahepatic Hepatoma Detected on MicroPET Using Copper (II)-64 Chloride Uptake Mediated by Endogenous Mouse Copper Transporter 1

Studies of 99mTc labeled carcinoembyronic antigen monoclonal antibody C50 fragment Fab' and biodistrobution

Radiolabeling and animal experimental studies of anti-breast cancer McAb 6C6 and mouse-human chimeric antibody 6C6CHI

Comparative Biodistribution of Potential Anti-Glioblastoma Conjugates [111In]dtpa-Hegf and [111In]bz-Dtpa-hegf in Normal Mice

Radiolabelling and Biological Evaluation of ~(99)Tc~m-mAb109 Against Breast Cancer

Preparation of ~(99)Tc~m-Dtpa-folate and Biodistribution Study in Athymic Mice

Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy

Tumor Radioimmunoimaging of Chimeric Antibody in Nude Mice with Hepatoma Xenograft.

Biodistribution and Pharmacokinetics of 99tcm Labeled Carbohydrated Peptides in Mice Bearing Tumors

Positron Emission Tomography Imaging of Tumor Angiogenesis with a (61/64)Cu-Labeled F(ab')(2) Antibody Fragment.

Animal SPECT/CT imaging and radiation dosimetry of~(99m)Tc-HYNIC-TOC

Pharmacokinetics of ~(131)I-Labeled-metuximab and Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma

Radiolabeling of Filamentous Phage Peptide Library with ~(99m)tc and Its Biodistribution in Normal Mice

Radioimmunoimaging and Biodistribution of ~(131)I Labeled Anti-Cea Monoclonal Antibody C50 in Nude Mice Bearing Human Breast Carcinoma Xenografts

Technetium-99m Labeling on Monoclonal Antibodies Via N,N'-Ethylene-Bis-L-Cysteine

Study of Distribution and Antisense Imaging for 99Mtc-Ason-egf in Breast Cancer-Bearing Nude Mouse Models

Small-Animal Spect/Ct Imaging with 99Mtc-Hynic-h10f Detects Her2 Expression in Mice Bearing Human Breast Cancers

An Experimental Study on Mice Bearing Liver Cancer Imaging with ~(99)Tc~m-Hl91

Biodistribution and Imaging of Radioiodinate Antihuman Tumor-derived IgG Light Chain Monoclonal Antibody in Nude Mice Bearing Tumor in Vivo

Toxicity of quantum dot-alpha-fetoprotein antibody probes and its metabolism in nude mice